TRT and Testicular Atrophy: Can Testicle Shrinkage Be Prevented?

Men starting TRT are often surprised when, after a few months, they notice the testicles are smaller, softer or sitting higher. For some it is a cosmetic matter, for others a source of anxiety about fertility and sexual function. It is worth separating at once two things that blur together in everyday talk: testicular size as a visible feature, and their function, meaning the production of sperm and hormones. The two are linked but are not the same.

This article focuses on what can be proven. We discuss the mechanism behind testicular shrinkage, show direct data from the study on hCG, explain what it did not show, and point to the practical consequences for a man considering or using TRT. Details of hCG dosing and other fertility-protection strategies can be found in the knowledge-base entries, not here — this text does not replace a treatment plan agreed with a doctor.

The testicles work under the control of the pituitary. Luteinizing hormone (LH) stimulates Leydig cells to produce testosterone, and follicle-stimulating hormone (FSH), together with a high local testosterone concentration, supports Sertoli cells and sustains spermatogenesis. The whole system works on negative feedback: when there is a lot of testosterone in the blood, the pituitary reduces secretion of LH and FSH. Exogenous testosterone in TRT is a 'we have enough' signal for this system, so gonadotropins fall and the testicles lose their stimulus.

Why does this lead to testicular shrinkage? Most of the volume of a testicle is made up of seminiferous tubules, where sperm are produced. When spermatogenesis weakens and Leydig cells are not stimulated, the tubules and interstitial tissue shrink, and the testicle gets smaller. This is a physiological phenomenon, not damage in the disease sense: the tissue is not destroyed but 'put to sleep'. In practice many men notice the change within the first months, but there are no reliable numerical data that would allow us to state the typical degree of shrinkage or the proportion of men affected.

The key concept is intratesticular testosterone (ITT). Under normal conditions the testicle makes so much of it that its concentration inside the organ is many times higher than in serum (in one study about 80-fold) — in studies of healthy men, blood testosterone was about 1.2% of the intratesticular concentration. It is this very high local level, not circulating testosterone, that sustains spermatogenesis. TRT raises the circulating level but at the same time destroys the conditions for ITT, which is why a man can have normal testosterone in the blood and markedly impaired testicular function.

Human chorionic gonadotropin (hCG) binds the same receptor as LH. If the pituitary no longer sends LH, hCG can play its role: stimulating Leydig cells to produce testosterone in the testicle. The question is what dose is enough to maintain ITT. The answer came from a study in which ITT was measured directly in fluid taken from the testicles by fine-needle aspiration.

What does this give us in practice? First, it is the strongest direct evidence that ITT can be maintained despite suppression of the axis, and that this is dose-dependent. Second, the result explains the mechanism behind the 'TRT with hCG' strategy: the signal in the testicles is restored, so in theory both function and volume should be preserved. Third, the study concerned healthy men for only 3 weeks, and the outcome assessed was the hormone concentration in the testicle, not testicular volume or sperm count. The authors themselves note that the ITT threshold needed for spermatogenesis remains to be established.

Data from treating patients complete the picture. In a retrospective series by Hsieh et al. (Journal of Urology, 2013), 26 hypogonadal men (mean age 35.9 years) were treated with testosterone by injection or gel together with 500 IU of hCG intramuscularly every other day. Serum testosterone rose on average from 207 to 1,056 ng/dl, and estradiol from 2.2 to 3.7 pg/ml (a difference not statistically significant). Semen parameters did not change during treatment, none of the men became azoospermic, and 9 of 26 contributed to a partner's pregnancy. The authors recall that without hCG, testosterone leads to azoospermia in about 40% of patients.

The series must be read cautiously: it was small, retrospective and without a control group, with a mean follow-up of 6.2 months. Assessment of testicular volume is not listed among the results in the abstract. Even so, agreement with the ITT study is consistent: where testicular function is sustained, semen parameters are better preserved. A 2025 review devoted to TRT and spermatogenesis in men of reproductive age points out that exogenous androgens drastically lower ITT and impair spermatogenesis, and that hCG, FSH, selective estrogen receptor modulators and aromatase inhibitors may in selected situations preserve or restore spermatogenesis — with the caveat that they need further study.

After testosterone is stopped, the hypothalamic–pituitary–testicular axis usually regains function and the testicles return to their previous size, but the pace of this process is highly variable. The 2025 review mentioned above stresses that sperm production often slowly resumes after TRT cessation, but the kinetics of recovery are highly variable and can complicate family planning. This means one cannot accurately predict after how many months or years the testicles will return to full function in a given man, and that in some people recovery is incomplete.

The pace of return may be affected by factors that are often outside the man's control, such as duration of therapy, age, and baseline fertility and testicular condition before treatment. For this reason, people who plan a child should discuss alternatives to classical TRT with their doctor rather than assume it will 'somehow rebuild'. We discuss the effect of TRT on fertility more broadly in a separate article on TRT and fertility and in the entry on male fertility.

There is no strategy that fully guarantees no change in testicular size during TRT, but there are options that in theory, or partly in studies, sustain their function. All require a doctor's decision and regular check-ups; the overview below is general information, not a treatment plan.

It is worth noting that hCG is not free of side effects: it also stimulates Leydig cells to produce estradiol, which in some men increases breast tenderness, fluid retention and mood swings, and doses must be individually tailored. In the series by Hsieh et al., mean estradiol rose, although the rise was not statistically significant. The detailed principles are covered in the entry on hCG in TRT and the article on combining TRT with hCG.

Equally wrong is the belief that it is enough to 'take hCG' and the problem disappears. hCG sustains testicular function, but it does not remove the need for monitoring, does not guarantee fertility, and there are no large studies showing that it preserves exactly the original volume. The most honest answer is: testicular shrinkage is a common consequence of TRT but largely reversible, and limiting it is possible — with the caveat that the evidence is mainly hormonal and indirect.

Remember the limits of the available data. The strong evidence concerns hormones inside the testicles in healthy men over a short period; data on actual testicular volume and the long-term effects of hCG are limited, and the clinical series on semen is small and retrospective. Every decision about protecting the testicles or fertility should therefore be made individually, on the basis of your own tests and a consultation with a specialist.

Testicular shrinkage on TRT is neither a flaw in execution nor a surprising adverse effect, but a predictable result of the body no longer sending the testicles a signal to work. Whether and how to prevent it depends on the man's goals: if fertility matters, a protection strategy should be discussed before the first dose; if not, the change is usually an acceptable trade-off. In both cases baseline tests, regular check-ups and knowing the warning signs are what count.